JD
Therapeutic Areas
Aytu BioScience Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Adzenys XR-ODT | Attention Deficit Hyperactivity Disorder (ADHD) | Approved/Commercial |
| Cotempla XR-ODT | Attention Deficit Hyperactivity Disorder (ADHD) | Approved/Commercial |
| ZTlido® | Postherpetic neuralgia (PHN) | Approved/Commercial |
| Karbinal™ ER | Infantile colic / Allergic Rhinitis | Approved/Commercial |
| AcipHex® Sprinkle | GERD, H. pylori eradication (pediatric) | Approved/Commercial |
| Nexafed / Nexafed Sinus | Sinus congestion and pain | Approved/Commercial |
| AR101 | Peanut Allergy | Phase 3 |
| Ryzodeg® | Type 1 & Type 2 Diabetes | Approved/Commercial |
Leadership Team at Aytu BioScience
JD
Josh Disbrow
Former Chairman and Chief Executive Officer
JD
Jarrett Disbrow
Former President and Director
MO
Mark Oki
Former Chief Financial Officer
DG
David Green
Former Chief Commercial Officer
V(
Vladimir (Ladd) Dragic
Former Chief Operating Officer
JG
John G. Cooper
Former Board Member
TM
True Merrill
Former Board Member